Olav Hellebo was appointed as Chief Executive Officer in September 2014. A highly experienced, international pharmaceutical executive he has broad commercial experience gained at both major pharmaceutical and small biotechnology companies. He has particular experience of the clinical development, out-licensing, commercialisation and marketing of new therapeutics.
Prior to ReNeuron, Olav held the role of CEO at Clavis Pharma ASA, a Norwegian, oncology focused, listed biotechnology company. At Clavis, Olav built a multi-national leadership team, taking the company’s lead programme through Phase III clinical development as well as completing substantial fundraising and out-licensing transactions for the business. Prior to Clavis, Olav headed up the global biologics franchise at UCB Pharma and was head of the UK commercial operations of Novartis. Olav started his pharmaceutical career in 1992 at Schering-Plough, where he held a number of senior commercial roles in Europe and the US, including leading its US commercial operations in the areas of oncology, cardiovascular and hepatitis-C, representing annual sales in excess of $2 billion. Olav has an MBA from the IESE Business School in Spain and a Bachelor of Business Administration from Hofstra University, USA.
Michael Hunt joined ReNeuron in 2001. Between 2005 and 2014 he served as its CEO, leading the business through its early development to its current position as one of the global, clinical-stage leaders in the regenerative medicine field. Prior to ReNeuron, he spent six years at Biocompatibles International plc (sold to BTG plc) where he held a number of senior financial and general management positions. His early industrial career was spent at Bunzl plc. He is a founding member and co-chair of the European Section of the Alliance for Regenerative Medicine and sits on the BioIndustry Association’s Cell Therapy and Regenerative Medicine Advisory Committee and its Finance and Tax Advisory Committee. He is a past Senior Industry Group member of the UK Government’s Office for Life Sciences. He currently sits as an industry member on the Department of Health’s Regenerative Medicine Expert Group and is a member of the Cell Therapy Catapult’s Advisory Panel. He read economics at University College London and qualified as a chartered accountant with Ernst & Young.
Dr. Sinden is a scientific co-founder of ReNeuron and from 1998 to 2015 was an executive director of the ReNeuron companies. Prior to founding ReNeuron and becoming its first employee, he was Reader in Neurobiology of Behaviour at the Institute of Psychiatry at Kings College London. He graduated in Psychology from the University of Sydney and completed a Ph.D. in Neuroscience from the University of Paris at the College de France. He subsequently held post-doctoral appointments at Oxford University and the Institute of Psychiatry prior to joining the permanent staff of the Institute in 1987. Dr. Sinden is an Honorary Professor in the Faculty of Medical Sciences at University College London and has over 140 scientific publications and book chapters. He holds Fellowships of the Royal Society of Medicine and the Royal Society of Biology and is a member of the International Society for Stem Cell Research and the Expert Working Group on Cell and Gene Therapies for the Bioindustry Organization BioSafe Committee.
Sharon Grimster joined ReNeuron in 2013 and was subsequently appointed as General Manager of the Wales facility in April 2015. Sharon has significant experience in pharmaceutical development, and she has a particular expertise in biologics manufacturing.
Prior to working at ReNeuron, Sharon held senior team roles at F-star and Antisoma, where she was responsible for a range of development functions, including project management, regulatory affairs , manufacturing, quality and general operations. Sharon started her pharmaceutical career at Celltech, where she led teams in project management, manufacturing and research.
Sharon recently qualified as a coach at the Henley Business school and has a B.Sc. from the University of Leicester and a Diploma in Management Studies. She is also an active member of a number of significant industry committees.
Randolph Corteling received his first degree (BSc Pharmacology (Hons)) from the University of East London in 1997. He then spent 3 years as a Research associate at Novartis pharmaceuticals in West Sussex, before undertaking a PhD in Medical and Surgical Sciences under the supervision of Prof. Ian Hall at Nottingham University. He then subsequently spent 3 years as a Heart and Stroke Foundation postdoctoral fellow at the University of Calgary, Canada before joining ReNeuron as a senior member of the research team in 2007. During his time at ReNeuron, Randolph has developed a number of new discoveries along with a thorough understanding of stem cell biology leading to his appointment as Head of Cell Biology in 2011 before subsequently being made Head of Research in April 2015.
Dr Julian Howell has held a number of leadership roles in clinical development during the last 15 years, bringing small molecules and biological products through all phases of clinical development in Europe and the US. He joins ReNeuron from Shield Therapeutics, where he held the role of Group Medical Director. Prior to that, he led the clinical team at ProStrakan, contributing to multiple US and EU new product approvals in oncology supportive care, GI and pain treatments. He gained medical and surgical qualifications in the UK and worked in the UK health service before completing an MBA at Cranfield University and joining the pharmaceutical industry, initially at SmithKlineBeecham and subsequently in senior clinical and medical affairs roles at Roche, Chiron and Pharmion.
Shaun Stapleton joins ReNeuron from RRG (a Voisin Consulting Life Sciences Company) where he was a Director and Vice President of Regulatory Science. He supported clients on a number of global development and registration projects, including advanced therapies and orphan drugs. Having graduated in Biochemistry from Imperial College, London, he began his career in research with the Imperial Cancer Research Fund, before moving into the pharmaceutical industry. He held positions of increasing responsibility in regulatory affairs at Sterling Winthrop, Eli Lilly and Boehringer Ingelheim before becoming Senior Director of Regulatory Affairs at Ipsen, where he managed regulatory input into development programmes globally, securing new product approvals in the US, EU and internationally in the neurology, endocrinology and oncology therapeutic areas.